Pharmacotherapy of osteoarthritis

American Journal of Physical Medicine and Rehabilitation

Volumn 85, Issue 11 SUPPL., 2006, Pages

  Stitik, Todd P ^a   Altschuler, Eric ^a   Foye, Patrick M ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Medications; Osteoarthritis; Pharmacotherapy; Treatment

Indexed keywords

BENGAY; CAPSAICIN; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; FLEXALL; LIDOCAINE; MENTHOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; ROFECOXIB; SALICYLIC ACID; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALDECOXIB; WARFARIN;

APPLICATION SITE IRRITATION; BLEEDING; CARDIOTOXICITY; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEMATOCHEZIA; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KNEE OSTEOARTHRITIS; KNEE PAIN; LIVER DYSFUNCTION; LIVER TOXICITY; MELENA; NAUSEA; NEUROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PAIN ASSESSMENT; PAIN THRESHOLD; PATIENT COMPLIANCE; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEDATION; SEIZURE; SOMNOLENCE; STROKE; SUSTAINED DRUG RELEASE; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

ACETAMINOPHEN; ADMINISTRATION, TOPICAL; ANALGESICS; ANESTHETICS, LOCAL; CAPSAICIN; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRA-ARTICULAR; LIDOCAINE; OSTEOARTHRITIS; SALICYLATES; TRAMADOL;

EID: 33750613295     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.phm.0000245512.85085.a0     Document Type: Review

References (119)

1. Altman R, Hochberg M, Moskowitz R, et al: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15
2. Flower RJ, Vane JR: Inhibition of prostaglandin synthetase in brain explains the anti-pyretic action of paracetamol (4-acetamidophenol). Nature 1972;240:410
3. Chandrasekharan NV, Dai H, Roos KL, et al: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-31
4. Kis B, Snipes JA, Busija DW: Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005;315:1-7
5. Benison H, Kaczynski J, Wallerstedt S: Paracetamol medication and alcohol abuse: a dangerous combination for the liver and the kidney. Scand J Gastroenterol 1987;22:701-4
6. Fored CM, Ejerblad E, Lindblad P, et al: Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001;345:1801-8
7. Henrich WL, Agodaoa LE, Barret B, et al: Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996;27:162-5
8. Forman JP, Stampfer MJ, Curhan JC: Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7
9. Hylek EM, Heiman H, Skates SJ, et al: Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-62
10. Fitzmaurice DA, Murray JA: Potentiation of the anticoagulant effect of warfarin. Postgrad Med J. 1997;73:439-40
11. Zhang W, Jones A, Doherty M: Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A metaanalysis of randomized controlled trials. Ann Rhem Dis 2004;63:901-7
12. Towheed TE, Judd MJ, Hochberg MC, et al: Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2003;(2):CD004257
13. Towheed TE, Maxwell L, Judd MG, et al: Acetaminophen for osteoarthritis. Cochrane System Review 2006;25:CD004257
14. Bradley JD, Brandt KD, Katz BP, et al: Comparison of an inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325:87-91
15. Williams HK, Ward JR, Egger MJ, et al: Comparison of naproxen and acetaminophen in the two-year study of the treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-206
16. Eccles M, Freemantle N, Mason J: North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. BMJ 1998;317:526-30
17. Pincus T, Swearingen C, Cummins P, et al: Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000;27:1020-7
18. Wolfe F, Zhao S, Lane N: Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000;43:378-85
19. Schnitzer TJ: Non-NSAID pharmacologic treatment options for the management of chronic pain. Am J Med 1998;105:45S-52S
20. Wiesenhutter CW , Boice JA, Ko A, et al: Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc 2005;80:470-9
21. Schiff M, Minic M: Comparison of the analgesic efficacy and safety of noprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee. J Rheumatology 2004;31:1373-83
22. Schnitzer TJ, Weaver AL, Polis AB, et al: Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheum 2005;32:1093-105
23. Konstantinopoulos PA, Lehmann DF: The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005;45:742-50
24. Moore RA, Derry S, Makinson GT, et al: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65
25. Drazen JM: COX-2 inhibitors - a lesson in unexpected problems. New Engl J Med 2005;352:1131-2
26. Brophy JM: Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005;4:1005-15
27. Grosser T, Fries S, Fitzgerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15
28. Kivitz AJ, Moskowitz RW, Woods E, et al: Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001;29:467-79
29. Goldstein JL, Correa P, Zhao WW, et al: Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27
30. McKenna F, Borenstein D, Wendt H, et al: Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scan J Rheumatol 2001;30:11-8
31. Roth SH: Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998;25:1358-63
32. Bianchi M, Broggini M, Balzarini P, et al: Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamol. Int Immunopharmacol. 2003;3:1901-8
33. Katz WA: Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs. 1996;52(Suppl):39-47
34. Ultram prescribing information. Product information pamphlet. Ortho-McNeil Pharmaceutical. 2000
35. Dalgin PH: Use of Tramadol in chronic pain. Clin Geriatr 1995;3:17-30
36. Kahn LH, Alderfer RJ, Graham DJ: Seizures reported with tramadol [Letter]. JAMA 1997;278:1661
37. Lazebnik LB, Kotsiubinskaia OB, Konev IuV, et al: Nonsteroidal anti-inflammatory drugs and tramadol in the treatment of osteoarthrosis deformans in patients with arterial hypertension. Klin Med (Mosk) 2004;82:56-61
38. Osipova NA, Novikov GA, Beresnev VA, et al: Analgesic effect of tramadol in patients with chronic pain: a comparison with prolonged-action morphine sulfate. Curr Ther Res 1991;50:812-21
39. Cicero TJ, Adams EH, Geller A, et al: A post-marketing surveilannce program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999;57:7-22
40. Dalgin P and the TPS-OA Study Group: Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis [Abstract]. Arthritis Rheum 1997;40(Suppl 9):S86.
41. Roth SH, Fleischmann RM, Burch FX, et al: Around-theclock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60
42. Schnitzer TJ, Kamin M, Olson WH: Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain. Arthritis Rheum 1999;42:1370-7
43. Katz WA, Rothenberg R: Treating the patient in pain. J Clin Rheumatol 2005;11(2 Suppl):S16-27
44. Emkey R, Rosenthal N, Wu SC, et al: Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol ;2004;31:150-6
45. Silverfield JC, Kamin M, Wu SC, et al: Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clin Ther 2002;24:282-97
46. Rosenthal NR, Silverfield JC, Wu SC, et al: Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population. J Am Geriatr Soc 2004;52:374-80
47. Mullican WS, Lacy JR: TRAMAP-ANAG-006 Study Group. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther 2001;23:1429-45
48. Malonne H, Coffiner M, Fontaine D, et al: Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther 2005;30:113-20
49. Malonne H, Coffiner M, Sonet B, et al: Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1774-82
50. Babul N, Noveck R, Chipman H, et al: Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28:59-71
51. Bodalia B, McDonald CJ, Smith KJ, et al: A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. J Pain Symptom Manage 2003;25:142-9
52. Adler L, McDonald C, O'Brien C, et al: A comparison of oncedaily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol 2002;29:2196
53. Goodwin JL, Kraemer JJ, Bajwa ZH: The use of opioids in the treatment of osteoarthritis: when, why, and how? Curr Pain Headache Rep 2005;9:390-8
54. Quiding H, Grimstad J, Rusten K, et al: Ibuprofen plus codeine, ibuprofen, and placebo in a single- and multidose crossover comparison for coxarthrosis pain. Pain 1992;50:303-7
55. Caldwell JR, Hale ME, Boyd RE, et al: Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9
56. Markenson JA, Croft J, Zhang PG, et al: Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005;21:524-35
57. Le Loet X, Pavelka K, Richarz U: Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study. BMC Musculoskelet Disord 2005;6:31
58. Pavelka K, Le Loet X, Bjorneboe O, et al: Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. Curr Med Res Opin 2004;20:1967-77
59. Stein A, Yassouridis A, Szopko C, et al: Intraarticular morphine versus dexamethasone in chronic arthritis. Pain 1999;83:525-32
60. Likar R, Schafer M, Paulak F, et al: Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Anesth Analg 1997;84:1313-7
61. Fraenkel L, Bogardus S, Concato J, et al: Treatment options in knee osteoarthritis: the patient's perspective. Arch Intern Med 2004;164:1299-304
62. Reinharth D: Capsaicin cream unpopular with patients. Arch Intern Med 2005;165:702
63. Rains C, Bryson HM: Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995;7:317-28
64. Fitzgerald M: Capsaicin and sensory neurones - a review. Pain 1983;15:109-30
65. Honore P, Wismer CT, Mikusa J, et al: A-425619 [1-isoquinolin-5-yl-3-(4- trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005;314:410-21
66. Dray A: Life Sci 1992;51:1759-65
67. Deal CL, Schnitzer TJ, Lipstein E, et al: Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991;13:383-95
68. Vilensky JA, Cook JA: Neurogenic acceleration of osteoarthritis. Curr Opin Rheumatol 1998;10:251-5
69. Matsubara T, Saura R, Uno K, et al: Modulation of articular metabolism by substance P: possible involvement of neural pathway in cartilage degradation, in Scientific Abstracts of the 54th Annual Meeting of the Amercian College of Rheumatology, Seattle, WA, October 27 to November 1, 1990
70. Matucci CM, McCarthy G, Lombardi A, et al: Neurogenic influences in arthritis: potential modification by capsaicin. J Rheumatol 1995;22:1447-9
71. Schnitzer TJ, Morton C, Coker S: Topical capsaicin therapy for osteoarthritis pain: achieving a maintenance regimen. Semin Arthritis Rheum 1994;23(Suppl):34-40
72. McCarthy GM, McCarty DJ: Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 1992;19:604-7
73. Zhang WY, Po ALW: The effectiveness of topically applied capsaicin: a meta-analysis. Eur J Clin Pharmacol 1994;46:517-22
74. McCleane G: The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled study. Eur J Pain 2000;4:355-60
75. McCleane GJ, McLaughlin M: The addition of GTN to capsaicin cream reduces the discomfort associated with application of capsaicin alone. A volunteer study. Pain 1998;78:149-51
76. Cake MA, Read RA, Appleyard RC, et al: The nitric oxide donor glyceryl trinitrate increases subchondral bone sclerosis and cartilage degeneration following ovine meniscectomy. Osteoarthr Cartil 2004;12:974-81
77. Kissin EY, Freitas CF, Kissin I: The effects of intraarticular resiniferatoxin in experimental knee-joint arthritis. Anesth Analg 2005;101:1433-9
78. Cross SE, Anderson C, Roberts MS: Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies. Br J Clin Pharmacol 1998;46:29-35
79. Eccles R: Menthol and related cooling compounds. J Pharm Pharmacol 1994;46:618-30
80. Martin D, Valdez J, Boren J, et al: J Clin Pharmacol. 2004;44:1151-7
81. Maune S, Frese KA, Mrowietz U, et al: Toxic inner ear damage in topical treatment of psoriasis with salicylates. Laryngorhinootologie 1997;76:368-70
82. Chodorowski Z, Anand JS, Waldman W: Suicidal salicylate intoxications and unintentional percutaneous poisoning with salicylic ointment. Przegl Lek 2003;60:302-4
83. Mason L, Moore RA, Edwards JE, et al: Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004;328:995
84. Algozzine GJ: JAMA 1982;247:1311-3
85. Baixauli F, Ingles F, Alcantara P, et al: Percutaneous treatment of acute soft tissue lesions with naproxen gel and ketoprofen gel. J Intern Med Res 1990;18:372-8
86. Gevi M, Merlo M: Ketoprofen lysine by topical route in sports traumatology. Curr Ther 1983;34:844-50
87. Glazier R, Steele L: Are topically applied nonsteroidal anti-inflammatory drugs effective and safe? Can Fam Physician 1999;45:1690-2
88. Sift Carter R, Ebner D, Brenner D, et al: Use of topical NSAIDs in patients receiving systemic NSAID treatment: a pharmacy-based study in Germany. J Clin Epidemiol 1997;50:217-8
89. Moore AR, Willoughby DA: Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 1995;17:153-6
90. Rolf C, Engstrom B, Beauchard C, et al: Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford) 1999 ; 38:564-7
91. Moore RA, Tramer MR, Carroll D, et al: Quantitative systematic review of topically-applied non-steroidal anti-inflammatory drugs. BMJ 1998;316:333-8
92. Roth SH: A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. Int J Tissue React 1995;17:129-32
93. Rovensky J, Micekova D, Gubzova Z, et al: Treatment of knee osteoarthritis with a topical non-steroidal antiinflammatory drug. Results of a randomized, double-blind, placebo-controlled study on the efficacy and safety of a 5% ibuprofen cream. Drugs Exp Clin Res 2001;27:209-21
94. Grace D, Rogers J, Skeith K, et al: Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999;26:2659-63
95. Solignac M: [Proof of the pharmacodynamic activity of Flector Plaster in healthy volunteers and patients suffering from osteo-arthritis of the knee.] Presse Med 2004;33:3S5-9
96. Trnavsky K, Fischer M, Vogtle-Junkert U, et al: Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis. Results of a randomized, double-blind, placebo-controlled study. J Rheumatol 2004;31:565-72
97. Bruhlmann P, Michel BA: Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clin Exp Rheumatol 2003;21:193-8
98. van Haselen RA, Fisher PA: A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. Rheumatology (Oxford) 2000;39:714
99. Bookman AA, Williams KS, Shainhouse JZ: Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 2004;171:333-8
100. Baer PA, Thomas LM, Shainhouse Z: Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 2005;6:44
101. Roth SH, Shainhouse JZ: Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004;164:2017-23
102. Ottillinger B, Gomor B, Michel BA, et al: Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. Osteoarthr Cartil 2001;9:273-80
103. Tugwell PS, Wells GA, Shainhouse JZ: Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31:2002-12
104. Sandelin J, Harilainen A, Crone H, et al: Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol 1997;26:287
105. Waikakul S, Penkitti P, Soparat K, et al: Topical analgesics for knee arthrosis: a parallel study of ketoprofen gel and diclofenac emulgel. J Med Assoc Thai 1997;80:593
106. Indurwede NH, Biyoni KR, Nekhat PD, et al: Formulation, evaluation and comparison of gels containing different COX-2 inhibitors. Indian J Med Sci 2001;55:549-52
107. Cutaneous reactions to topical NSAIDs. Prescrire Int 2000;9:114-5
108. Baudot S, Milpied B, Larousse C: Cutaneous side effects of ketoprofen gels: results of a study based on 337 cases. Therapie 1998;53:137-44
109. Dieppe P, Chard J, Faulkner A, et al: Osteoarthritis, in United Health Foundation (eds): Clinical Evidence: The International Source of the Best Available Evidence for Effective Health Care, vol 3. London: BMJ Publishing Group, 2000, 529-41
110. Evans JM, McMahon AD, McGilchrist MM, et al: Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995;311:22-6
111. Hines R, Keaney D, Moskowitz MH, et al: Use of lidocaine patch 5% for chronic low back pain: a report of four cases. Pain Med 2002;3:361-5
112. Burch F, Codding C, Patel N, et al: Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, openlabel effectiveness trial. Osteoarthr Cartil 2004;12:253-5
113. Gammaitoni AR, Galer BS, Onawola R, et al: Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004;20(Suppl 2):S13-9
114. Galer BS, Rowbotham MC, Perander J, et al: Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle. Topical patch: results of an enriched enrollment study. Pain 1999;80:533-8
115. Laird JM, Carter AJ, Grauert M, et al: Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol 2001;134:1742-8
116. Argoff CE: New analgesics for neuropathic pain: the lidocaine patch. Clin J Pain 2000;16(2 Suppl):S62-6
117. Gammaitoni AR, Alvarez NA, Galer BS: Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43:111-7
118. Galer BS: Effectiveness and safety of lidocaine 5% patch. Family Pract 2002;51:867
119. Lidoderm package insert. Product information pamphlet. Endo Pharmaceuticals. 2006